Scarica l'app Stockscreener
2.56
8.94%
0.21
Dopo l'orario di chiusura:
2.54
-0.02
-0.78%
Precedente Chiudi:
$2.35
Aprire:
$2.4752
Volume 24 ore:
2.75M
Relative Volume:
0.49
Capitalizzazione di mercato:
$871.07M
Reddito:
-
Utile/perdita netta:
$-75.80M
Rapporto P/E:
-7.3143
EPS:
-0.35
Flusso di cassa netto:
$-68.07M
1 W Prestazione:
+14.80%
1M Prestazione:
+26.11%
6M Prestazione:
-7.58%
1 anno Prestazione:
-21.95%
Intervallo 1D:
$2.47
$2.57
Intervallo di 1 settimana:
$2.20
$2.57
Portata 52W:
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
Nome
Nuvation Bio Inc
Settore
Industria
Telefono
(415) 754-3517
Indirizzo
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Confronta NUVB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.56 | 799.62M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-23 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-26 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2021-03-08 | Iniziato | BTIG Research | Buy |
| 2021-03-08 | Iniziato | Cowen | Outperform |
| 2021-03-08 | Iniziato | Jefferies | Buy |
| 2021-03-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Nuvation Bio Inc Borsa (NUVB) Ultime notizie
What drives Nuvation Bio Inc. stock priceConsistent high-performance stocks - Autocar Professional
Is Nuvation Bio Inc. a good long term investmentFree Consultation - Autocar Professional
Nuvation Bio Inc. Stock Analysis and ForecastFree Stock Index Interpretation - Autocar Professional
What analysts say about Nuvation Bio Inc. stockTremendous gains - jammulinksnews.com
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Breakthrough for IDH1 Mutant Glioma - TipRanks
Will Nuvation Bio Inc. stock benefit from interest rate changesLong Term Low Risk Growth - Newser
Is Nuvation Bio Inc. stock a good hedge against inflationFree Investing Community - Newser
Why Nuvation Bio Inc. stock attracts strong analyst attentionLow Risk Entry Points - beatles.ru
Nuvation Bio's Mysterious 5% Surge: A Deep Dive into the Unseen Drivers - AInvest
What makes Nuvation Bio Inc. stock price move sharplyIntraday Trade Ideas - Newser
How Nuvation Bio Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy - MSN
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Nuvation Bio's 16% Surge: A Deep Dive Into the Unseen Drivers - AInvest
Nuvation Bio's 11% Spike: A Deep Dive into the Unseen Drivers - AInvest
Nuvation Bio’s 7% Surge: A Technical and Market Flow Deep-Dive - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: IBTROZI approval boosts stock prospects - Investing.com
Positive week for Nuvation Bio Inc. (NYSE:NUVB) institutional investors who lost 31% over the past year - simplywall.st
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating - MSN
JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans - MSN
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2500 Growth Index - MarketScreener
Nuvation Bio Inc.(NYSE: NUVB) added to Russell 2000 Growth Index - MarketScreener
Digging for Diamonds in Biotech: Why Insider Buys Signal Opportunity in Nuvation Bio and Ardelyx - AInvest
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio stock rating reiterated at Market Outperform by Citizens JMP - Investing.com South Africa
Nuvation Bio's Taletrectinib Emerges as a Niche Oncology Leader with NCCN Endorsement - AInvest
Nuvation Bio (NUVB) Gains NCCN Endorsement for Taletrectinib in - GuruFocus
Boston Herald - FinancialContent
Nuvation Bio's Mysterious 10% Surge: A Technical & Market Flow Deep Dive - AInvest
Nuvation Bio jumps after insiders purchase shares worth over $1.1M - MSN
Nuvation Bio’s Mysterious 7% Surge: What’s Behind the Volatility? - AInvest
Wealth Enhancement Advisory Services LLC Buys Shares of 10,140 Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com India
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio Inc Azioni (NUVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):